Neogen Corporation Retained Earnings 2011-2026 | NEOG

Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.

Possible uses include

reinvestment in development (R&D, equipment, marketing)
debt repayment
acquisition of other companies
creation of reserves for the future

A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.

The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.

Annual Retained Earnings Neogen Corporation

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-536 M	556 M	565 M	588 M	540 M	479 M	419 M	359 M	296 M	252 M	216 M	182 M	154 M	127 M	104 M

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
588 M	-536 M	287 M

Quarterly Retained Earnings Neogen Corporation

2025-Q4	2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-516 M	-500 M	-536 M	75.8 M	86.7 M	543 M	556 M	561 M	563 M	567 M	565 M	559 M	551 M	593 M	588 M	573 M	568 M	557 M	540 M	540 M	510 M	495 M	479 M	462 M	450 M	434 M	419 M	419 M	390 M	374 M	359 M	359 M	325 M	308 M	296 M	296 M	273 M	262 M	252 M	252 M	234 M	225 M	216 M	216 M	199 M	191 M	182 M	182 M	168 M	162 M	154 M	154 M	140 M	133 M	127 M	127 M	115 M	110 M	104 M	104 M

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
593 M	-536 M	295 M

Retained Earnings of other stocks in the Diagnostics research industry

Issuer	Retained Earnings	Price	% 24h	Market Cap	Country
Centogene N.V. CNTG	-62.9 M	-	-6.23 %	$ 30.6 M	Germany
Agilent Technologies A	348 M	$ 113.95	-0.77 %	$ 34.6 B	USA
Fulgent Genetics FLGT	590 M	$ 16.09	-2.01 %	$ 486 M	USA
Guardant Health GH	-2.99 B	$ 91.82	2.4 %	$ 11.5 B	USA
ICON Public Limited Company ICLR	2.72 B	$ 107.77	-1.69 %	$ 8.89 B	Irlanda
Illumina ILMN	-1.24 B	$ 126.91	-0.65 %	$ 20.2 B	USA
CareDx, Inc CDNA	-735 M	$ 17.63	-1.07 %	$ 939 M	USA
Laboratory Corporation of America Holdings LH	8.64 B	$ 271.15	-1.21 %	$ 22.6 B	USA
Oxford Immunotec Global PLC OXFD	-84 M	-	-	$ 562 M	Britain
Lantheus Holdings LNTH	680 M	$ 77.17	1.68 %	$ 5.21 B	USA
Medpace Holdings MEDP	-460 M	$ 506.33	2.08 %	$ 14.6 B	USA
Danaher Corporation DHR	46.9 B	$ 190.17	-1.01 %	$ 136 B	USA
DexCom DXCM	2.43 B	$ 62.92	-0.46 %	$ 24.6 B	USA
Akumin AKU	-280 M	-	-17.87 %	$ 25.9 M	Canada
Burning Rock Biotech Limited BNR	-2.23 B	$ 16.29	-0.09 %	$ 175 M	China
Myriad Genetics MYGN	-1.12 B	$ 4.68	0.21 %	$ 433 M	USA
NeoGenomics NEO	-434 M	$ 8.0	-0.25 %	$ 1.02 B	USA
National Research Corporation NRC	-17.3 M	$ 17.17	-0.95 %	$ 384 M	USA
Co-Diagnostics CODX	-80.4 M	$ 4.4	101.83 %	$ 5.85 M	USA
Natera NTRA	-1.94 B	$ 206.84	0.96 %	$ 20.4 B	USA
Aspira Women's Health AWH	-544 M	-	-6.19 %	$ 10.5 M	USA
Accelerate Diagnostics AXDX	-607 M	-	-61.36 %	$ 2.46 M	USA
Pacific Biosciences of California PACB	-2.7 B	$ 1.44	1.41 %	$ 432 M	USA
Global Cord Blood Corporation CO	2.89 B	-	-	$ 399 M	China
Precipio PRPO	-103 M	$ 26.48	1.92 %	$ 42.5 M	USA
Fluidigm Corporation FLDM	-624 M	-	1.08 %	$ 308 M	USA
Personalis PSNL	-550 M	$ 6.09	-7.45 %	$ 361 M	USA
Genetic Technologies Limited GENE	-150 M	-	-	$ 7.1 B	Australia
Genetron Holdings Limited GTH	-4.94 B	-	0.12 %	$ 80.1 M	China
Charles River Laboratories International CRL	1.39 B	$ 168.25	0.02 %	$ 8.34 B	USA
PRA Health Sciences, Inc. PRAH	440 M	-	-	$ 10.7 B	USA
Sotera Health Company SHC	-532 M	$ 14.65	-1.51 %	$ 4.16 B	USA
Soleno Therapeutics SLNO	-431 M	$ 52.24	-0.03 %	$ 2.65 B	USA
Castle Biosciences CSTL	-200 M	$ 24.9	0.69 %	$ 692 M	USA
Neuronetics STIM	-459 M	$ 1.54	-12.5 %	$ 102 M	USA
Biocept BIOC	-298 M	-	-13.05 %	$ 7.29 M	USA
Biodesix BDSX	-462 M	$ 14.47	-5.79 %	$ 1.88 B	USA
Thermo Fisher Scientific TMO	59.2 B	$ 486.01	-0.45 %	$ 183 B	USA
Trinity Biotech plc TRIB	10.6 M	$ 0.6	-2.28 %	$ 61.9 M	Irlanda
VolitionRx Limited VNRX	-253 M	$ 0.17	-0.33 %	$ 21.4 M	Singapore
Waters Corporation WAT	10.4 B	$ 303.06	-0.34 %	$ 18 B	USA
QIAGEN N.V. QGEN	2.75 B	-	-	$ 10.6 B	Niderland
Anixa Biosciences ANIX	-252 M	$ 2.67	3.09 %	$ 86.7 K	USA
Biomerica BMRA	-53.2 M	$ 2.14	-1.38 %	$ 4.92 M	USA
BioNano Genomics BNGO	-720 M	$ 1.15	-0.24 %	$ 6.26 M	USA
Interpace Biosciences IDXG	-211 M	$ 2.0	1.27 %	$ 8.85 M	USA
Check-Cap Ltd. CHEK	-170 M	-	-	$ 9.42 M	Israel
Celcuity CELC	-449 M	$ 115.53	1.14 %	$ 5.4 B	USA